Omnicell Q2 revenue up 5%, hikes FY forecast

Omnicell

31/07/2025 11:44

Overview

Omnicell Q2 2025 revenue rises 5% yr/yr to $291 mln, driven by connected devices

Company exceeds guidance for non-GAAP EBITDA and EPS, reflecting strong performance

Omnicell raises full-year 2025 guidance for total revenues, non-GAAP EBITDA, and EPS

Outlook

Omnicell raises full-year 2025 revenue guidance to $1.130 bln - $1.160 bln

Company expects Q3 2025 revenue between $290 mln and $300 mln

Omnicell sees full-year non-GAAP EPS at $1.40 - $1.65

Company forecasts Q3 non-GAAP EPS at $0.30 - $0.37

Company forecasts Q3 non-GAAP EBITDA of $28 mln - $32 mln

Result Drivers

CONNECTED DEVICES - Strong demand for XT Series automated dispensing cabinets and XTExtend console drove revenue growth

NEW PRODUCTS - Introduction of MedTrack RFID Line and MedVision inventory management solution contributed to results

REVENUE DRIVERS - Growth in connected devices, technical services, SaaS and Expert Services, and consumables revenues fueled revenue increase

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$291 mln
Q2 Adjusted Net Income
$21 mln
Q2 Net Income
$6 mln
Q2 Adjusted EBITDA
$38 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Omnicell Inc is $44.00, about 32.5% above its July 30 closing price of $29.70

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nBw1FSJyXa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)